IceCure Medical develops and markets minimally invasive cryoablation therapies for women’s health. Our proprietary IceSense3™ system (FDA and CE Approved) provides a minimally-invasive, in-office definitive treatment, currently for symptomatic breast fibroadenoma (a benign breast tumor) and the same device is currently being used in several clinical studies for the treatment of small breast cancer tumors.
The IceSense3™ procedure is an attractive alternative to the current standard treatment of open surgical excision. The IceSense3™ procedure uses ultrasound imaging to guide a small probe (thin hollow needle) into the lesion. The system then uses extremely cold temperatures to destroy (ablate) the targeted lesion in situ. The IceSense3™ cryoablation procedure is a safe and effective treatment option that has the following characteristics:
- Performed by one physician
- An office procedure
- Local anesthesia
- Can be completed in 5-15 minutes
- No pain
- No scar, superior cosmetic results
- Short recovery time
- Promising treatment for small breast cancer tumors (under clinical studies in Japan and the U.S)
IceCure Medical Ltd. Is an Israeli company that markets and sells its products through its U.S subsidiary IceCure Medical, Inc. having its office in Memphis, Tennessee.
Recently, clinical results from a study of treatment of small breast cancer tumors were published, showing no cancer recurrence after follow-up period of up to 6 years. In 2014, IceCure intends to penetrate new markets in Europe, Asia and South America.
IceCure’s regulatory approvals cover broad indications (benign and malignant) in many areas that potentially can be treated by its superior 3rd generation cryoablation technology. The company is in advanced stage in the regulatory process in China (CFDA) as well as other countries.
The company’s core technology can be used also in other areas such as tumors in kidney, liver, lung, prostate as well as atrial fibrillation.